LQDA Stock Down Post Q2 Earnings Release: What Should Investors Do Now?

Total revenues surged to $171.7 million from $8.8 million a year ago and surpassed the Zacks Consensus Estimate of $165 million, driven by continued adoption of its lead drug, Yutrepia.

Despite the earnings and revenue beats, investors appeared unimpressed, likely due to the relatively modest magnitude of the upside versus expectations.

The recent weakness has added to LQDA’s underperformance over the past month. Shares have lost 3.5% during this period compared to a 4.5% gain for the industry. The stock has also lagged the broader sector and the S&P 500 Index.

LQDA Underperforms Industry, Sector and S&P 500 Index

Image Source: Zacks Investment Research

Against this backdrop, a closer examination of Liquidia’s key strengths and potential challenges could help investors determine whether the stock remains an attractive investment opportunity.

LQDA’s Yutrepia Gains Traction

Launched in June 2025, Yutrepia was approved by the FDA in May 2025 for the treatment of both pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

The drug is an inhaled dry-powder version of treprostinil made with the company’s proprietary PRINT technology, designed to deliver medicine deeper into the lungs through an easy-to-use inhaler and allow higher doses than other inhaled treprostinil treatments.

Yutrepia net product sales reached $170.4 million in the second quarter, up from $6.5 million a year earlier, driven by higher Yutrepia volume. Product sales increased 31.0% sequentially.

As of July 31, 2026, Liquidia had received approximately 5,900 unique prescriptions since launch and started more than 5,000 patients on therapy.

More than 1,100 physicians had prescribed Yutrepia since its launch as of July 31, with more than 30% having written prescriptions for at least five patients. The prescription-to-start conversion rate remained above 85%.

Strong Yutrepia sales helped drive the company's fourth consecutive profitable quarter, with net income reaching $74.7 million in the second quarter.

Yutrepia appears to be gaining market share while expanding the inhaled prostacyclin market.

Liquidia currently generates revenues from sales of Yutrepia inhalation powder, and through a profit-sharing arrangement with Sandoz under a promotion agreement originally signed in August 2018 and subsequently amended. The agreement allows Liquidia to share in the profits generated from sales of Sandoz's generic Treprostinil Injection in the United States.

LQDA plans to explore Yutrepia in additional indications, including pulmonary hypertension associated with chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, progressive pulmonary fibrosis and Raynaud’s phenomenon associated with systemic sclerosis.

Liquidia is leveraging its expertise in respiratory and vascular diseases to advance a pipeline of novel therapies that could support long-term growth. A key pipeline asset is L606, an investigational liposomal formulation of treprostinil licensed from Pharmosa Biopharm, designed for twice-daily administration using a short-duration, next-generation nebulizer. It is also being evaluated in PAH and PH-ILD. The phase III Re-Spire study on L606 is currently enrolling.

LQDA’s Overdependence on Yutrepia

While Yutrepia is driving LQDA’s top-line growth, the company remains heavily dependent on the drug as its primary growth driver. LQDA’s relatively lean pipeline further increases this concentration risk.

Liquidia is also involved in a patent dispute with United Therapeutics UTHR over Yutrepia’s use in PH-ILD. Management said an adverse ruling could result in a royalty or other injunctive/adjunctive relief. A decision could come at any time, so this is a binary risk that could affect Yutrepia economics or commercialization.

LQDA’s Valuation and Estimate Movement

Going by the price/sales ratio, LQDA shares currently trade at 6.89X forward sales, higher than the industry’s average of 1.94X but lower than its mean of 14.68X.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for 2026 earnings per share has moved south to $2.57 from $2.97 and that for 2027 EPS has declined to $4.38 from $4.81 in the past 60 days.

Image Source: Zacks Investment Research

Avoid LQDA Stock Now 

Liquidia's products and pipeline candidates for PAH compete across several established and clinically validated treatment pathways. UTHR markets four medicines in the United States to treat PAH, namely Remodulin, an injectable formulation of treprostinil, Orenitram, an oral version of treprostinil, Tyvaso, an inhaled version of treprostinil, and Adcirca (tadalafil; under an in-license from Eli Lilly and Company) tablets. Remodulin is approved for both subcutaneous (SC) and intravenous (IV) use.

Johnson & Johnson’s JNJ Uptravi (selexipag) is approved to treat PAH. JNJ has another PAH drug in its portfolio, named Opsumit.

Despite Yutrepia’s strong launch, Liquidia’s investment case carries several risks. The company remains heavily dependent on Yutrepia, with a relatively lean pipeline, making any slowdown in prescriptions, reimbursement challenges or competitive pressure a significant threat to growth.

The ongoing patent litigation with UTHR over Yutrepia’s PH-ILD indication is another major overhang. Competition from established PAH therapies could also limit Yutrepia’s market-share gains.

While 2026 and 2027 EPS estimates have declined, rising R&D spending could pressure future profitability.

Overall, LQDA’s high dependence on Yutrepia, litigation risk, competitive pressures, elevated valuation and rising costs create an unfavorable risk-reward profile.

Hence, we advise current and prospective investors to avoid the stock for now.

LQDA has a Zacks Rank #4 (Sell) at present.

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research